{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:30:50Z","timestamp":1771662650114,"version":"3.50.1"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Sj\u00f6gren\u2019s syndrome (SjS) is a frequent systemic autoimmune disease responsible for a major decrease in patients\u2019 quality of life, potentially leading to life-threatening conditions while facing an unmet therapeutic need. Hence, we assessed the immunogenicity, efficacy, and tolerance of IFN-Kinoid (IFN-K), an anti-IFN\u03b1 vaccination strategy, in a well-known mouse model of systemic autoimmunity with SjS-like features: MRL\/MpJ-Faslpr\/lpr (MRL\/lpr) mice. Two cohorts (with ISA51 or SWE01 as adjuvants) of 26 female MRL\/lpr were divided in parallel groups, \u201ccontrols\u201d (not treated, PBS and Keyhole Limpet Hemocyanin [KLH] groups) or \u201cIFN-K\u201d and followed up for 122 days. Eight-week-old mice received intra-muscular injections (days 0, 7, 28, 56 and 84) of PBS, KLH or IFN-K, emulsified in the appropriate adjuvant, and blood samples were serially collected. At sacrifice, surviving mice were euthanized and their organs were harvested for histopathological analysis (focus score in salivary\/lacrimal glands) and IFN signature evaluation. SjS-like features were monitored. IFN-K induced a disease-modifying polyclonal anti-IFN\u03b1 antibody response in all treated mice with high IFN\u03b1 neutralization capacities, type 1 IFN signature\u2019s reduction and disease features\u2019 (ocular and oral sicca syndrome, neuropathy, focus score, glandular production of BAFF) improvement, as reflected by the decrease in Murine Sj\u00f6gren\u2019s Syndrome Disease Activity Index (MuSSDAI) modelled on EULAR Sj\u00f6gren\u2019s Syndrome Disease Activity Index (ESSDAI). No adverse effects were observed. We herein report on the strong efficacy of an innovative anti-IFN\u03b1 vaccination strategy in a mouse model of SjS, paving the way for further clinical development (a phase IIb trial has just been completed in systemic lupus erythematosus with promising results).<\/jats:p>","DOI":"10.3389\/fimmu.2021.666134","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T07:38:24Z","timestamp":1637134704000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Therapeutic Potential of Anti-Interferon \u03b1 Vaccination on SjS-Related Features in the MRL\/lpr Autoimmune Mouse Model"],"prefix":"10.3389","volume":"12","author":[{"given":"Martin","family":"Killian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabien","family":"Colaone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Haumont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole","family":"Nicco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Cerles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Chouzenoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Cath\u00e9bras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Rochereau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blandine","family":"Chanut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireille","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Laroche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabien","family":"Forest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9raldine","family":"Grouard-Vogel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Batteux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205375","article-title":"Epidemiology of Primary Sj\u00f6gren\u2019s Syndrome: A Systematic Review and Meta-Analysis","volume":"74","author":"Qin","year":"2015","journal-title":"Ann Rheumatol Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2013.11.001","article-title":"A Comprehensive Review of Autoantibodies in Primary Sj\u00f6gren\u2019s Syndrome: Clinical Phenotypes and Regulatory Mechanisms","volume":"51","author":"Kyriakidis","year":"2014","journal-title":"J Autoimmun"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e3821","DOI":"10.1136\/bmj.e3821","article-title":"Primary Sjogren Syndrome","volume":"344","author":"Ramos-Casals","year":"2012","journal-title":"BMJ"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket349","article-title":"Systemic Involvement in Primary Sj\u00f6gren\u2019s Syndrome Evaluated by the EULAR-SS Disease Activity Index: Analysis of 921 Spanish Patients (GEAS-SS Registry)","volume":"53","author":"Ramos-Casals","year":"2014","journal-title":"Rheumatology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/annrheumdis-2014-206418","article-title":"Systemic Activity and Mortality in Primary Sj\u00f6gren Syndrome: Predicting Survival Using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 Patients","author":"Brito-Zer\u00f3n","year":"2014","journal-title":"Ann Rheumatol Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2016.100","article-title":"Treatment of Primary Sj\u00f6gren Syndrome","volume":"12","author":"Saraux","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2013.12.010","article-title":"Outcome Measures for Primary Sj\u00f6gren\u2019s Syndrome: A Comprehensive Review","volume":"51","author":"Seror","year":"2014","journal-title":"J Autoimmun"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209589","article-title":"Contrasting Expression Pattern of RNA-Sensing Receptors TLR7, RIG-I and MDA5 in Interferon-Positive and Interferon-Negative Patients With Primary Sj\u00f6gren\u2019s Syndrome","volume":"76","author":"Maria","year":"2017","journal-title":"Ann Rheumatol Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.10.006","article-title":"Type I Interferons in Sj\u00f6gren\u2019s Syndrome","volume":"12","author":"Yao","year":"2013","journal-title":"Autoimmun Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201381","article-title":"Prevalence of Interferon Type I Signature in CD14 Monocytes of Patients With Sjogren\u2019s Syndrome and Association With Disease Activity and BAFF Gene Expression","volume":"72","author":"Brkic","year":"2013","journal-title":"Ann Rheumatol Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jaut.2015.07.002","article-title":"Type I and II Interferon Signatures in Sjogren\u2019s Syndrome Pathogenesis: Contributions in Distinct Clinical Phenotypes and Sjogren\u2019s Related Lymphomagenesis","volume":"63","author":"Nezos","year":"2015","journal-title":"J Autoimmun"},{"key":"B12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jaut.2013.04.005","article-title":"B-Cell Activating Factor Genetic Variants in Lymphomagenesis Associated With Primary Sjogren\u2019s Syndrome","volume":"51","author":"Nezos","year":"2014","journal-title":"J Autoimmun"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40169-018-0218-1","article-title":"Clinical Features of Sj\u00f6gren\u2019s Syndrome Patients With Autoantibodies Against Interferons","volume":"8","author":"Burbelo","year":"2019","journal-title":"Clin Transl Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and Safety of Belimumab in Primary Sj\u00f6gren\u2019s Syndrome: Results of the BELISS Open-Label Phase II Study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann Rheumatol Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2015.11.002","article-title":"Blood and Salivary-Gland BAFF-Driven B-Cell Hyperactivity is Associated to Rituximab Inefficacy in Primary Sj\u00f6gren\u2019s Syndrome","volume":"67","author":"Cornec","year":"2016","journal-title":"J Autoimmun"},{"key":"B16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.clim.2017.05.002","article-title":"The Value of Rituximab Treatment in Primary Sj\u00f6gren\u2019s Syndrome","volume":"182","author":"Verstappen","year":"2017","journal-title":"Clin Immunol Orlando Fla"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214720","article-title":"Treatment of Primary Sj\u00f6gren\u2019s Syndrome With Ianalumab (VAY736) Targeting B Cells by BAFF Receptor Blockade Coupled With Enhanced, Antibody-Dependent Cellular Cytotoxicity","volume":"78","author":"D\u00f6rner","year":"2019","journal-title":"Ann Rheumatol Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/art.40589","article-title":"JAK-1 Inhibition Suppresses Interferon-Induced BAFF Production in Human Salivary Gland: Potential Therapeutic Strategy for Primary Sj\u00f6gren\u2019s Syndrome","volume":"70","author":"Lee","year":"2018","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0900615106","article-title":"IFNalpha Kinoid Vaccine-Induced Neutralizing Antibodies Prevent Clinical Manifestations in a Lupus Flare Murine Model","volume":"106","author":"Zagury","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/art.37785","article-title":"Down-Regulation of Interferon Signature in Systemic Lupus Erythematosus Patients by Active Immunization With Interferon \u03b1-Kinoid","volume":"65","author":"Lauwerys","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew262","article-title":"Interferon \u03b1 Kinoid Induces Neutralizing Anti-Interferon \u03b1 Antibodies That Decrease the Expression of Interferon-Induced and B Cell Activation Associated Transcripts: Analysis of Extended Follow-Up Data From the Interferon \u03b1 Kinoid Phase I\/II Study","volume":"55","author":"Ducreux","year":"2016","journal-title":"Rheumatol Oxf Engl"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216379","article-title":"IFN-\u03b1 Kinoid in Systemic Lupus Erythematosus: Results From a Phase IIb, Randomised, Placebo-Controlled Study","volume":"79","author":"Houssiau","year":"2020","journal-title":"Ann Rheumatol Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2014.02.006","article-title":"Sj\u00f6gren\u2019s Syndrome: Where do We Stand, and Where Shall We Go","volume":"51","author":"Cornec","year":"2014","journal-title":"J Autoimmun"},{"key":"B24","doi-asserted-by":"publisher","first-page":"549107","DOI":"10.1155\/2011\/549107","article-title":"Current Concepts: Mouse Models of Sj\u00f6gren\u2019s Syndrome","volume":"2011","author":"Lavoie","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2174\/1381612821666150316120024","article-title":"Mouse Models of Primary Sj\u00f6gren\u2019s Syndrome","volume":"21","author":"Park","year":"2015","journal-title":"Curr Pharm Des"},{"key":"B26","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/ar3313","article-title":"Sj\u00f6gren\u2019s Syndrome: Studying the Disease in Mice","volume":"13","author":"Delaleu","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3109\/08916939608995349","article-title":"Cytokine Gene Expression and Autoantibody Production in Sj\u00f6gren\u2019s Syndrome of MRL\/lpr Mice","volume":"23","author":"Hayashi","year":"1996","journal-title":"Autoimmunity"},{"key":"B28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jaut.2014.01.030","article-title":"CD4(-)CD8(-) T-Cells in Primary Sj\u00f6gren\u2019s Syndrome: Association With the Extent of Glandular Involvement","volume":"51","author":"Alunno","year":"2014","journal-title":"J Autoimmun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.02.001","article-title":"Tcr\u03b1\u03b2+CD3+CD4-CD8- (Double Negative) T Cells in Autoimmunity","volume":"17","author":"Brandt","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0604827103","article-title":"TNFalpha Kinoid Vaccination-Induced Neutralizing Antibodies to TNFalpha Protect Mice From Autologous TNFalpha-Driven Chronic and Acute Inflammation","volume":"103","author":"Le Buanec","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2007.070388","article-title":"Autoimmune Dacryoadenitis of NOD\/LtJ Mice and its Subsequent Effects on Tear Protein Composition","volume":"171","author":"Doyle","year":"2007","journal-title":"Am J Pathol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jneumeth.2015.08.010","article-title":"Practical Mechanical Threshold Estimation in Rodents Using Von Frey Hairs\/Semmes\u2013Weinstein Monofilaments: Towards a Rational Method","volume":"255","author":"Bradman","year":"2015","journal-title":"J Neurosci Methods"},{"key":"B33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1744-8069-5-9","article-title":"Mice With Cisplatin and Oxaliplatin-Induced Painful Neuropathy Develop Distinct Early Responses to Thermal Stimuli","volume":"5","author":"Ta","year":"2009","journal-title":"Mol Pain"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.08.015","article-title":"Neuropsychiatric Systemic Lupus Erythematosus and Cognitive Dysfunction: The MRL-Lpr Mouse Strain as a Model","volume":"13","author":"Jeltsch-David","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.110619","article-title":"EULAR Sjogren\u2019s Syndrome Disease Activity Index: Development of a Consensus Systemic Disease Activity Index for Primary Sjogren\u2019s Syndrome","volume":"69","author":"Seror","year":"2010","journal-title":"Ann Rheumatol Dis"},{"key":"B36","article-title":"Sialadenitis in the MRL-L Mouse: Morphological and Immunohistochemical Characterization of Resident and Infiltrating Cells","volume":"60","author":"Jonsson","year":"1987","journal-title":"Immunology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1006\/jaut.2002.0617","article-title":"TNFalpha Inhibition in MRL\/lpr Mice Ameliorates Pulmonary But Not Renal Disease","volume":"19","author":"Kim","year":"2002","journal-title":"J Autoimmun"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods San Diego Calif"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.12083","article-title":"BXSB\/MpJ-Yaa Mice Develop Autoimmune Dacryoadenitis With the Appearance of Inflammatory Cell Marker Messenger RNAs in the Lacrimal Fluid","volume":"41","author":"Kosenda","year":"2013","journal-title":"Clin Experiment Ophthalmol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402071","article-title":"MF59 Mediates Its B Cell Adjuvanticity by Promoting T Follicular Helper Cells and Thus Germinal Center Responses in Adult and Early Life","volume":"194","author":"Mastelic Gavillet","year":"2015","journal-title":"J Immunol Baltim Md 1950"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1495301","article-title":"Immunology and Efficacy of MF59-Adjuvanted Vaccines","volume":"14","author":"Ko","year":"2018","journal-title":"Hum Vaccines Immunother"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2015.03","article-title":"Identification of an Ideal Adjuvant for Receptor-Binding Domain-Based Subunit Vaccines Against Middle East Respiratory Syndrome Coronavirus","volume":"13","author":"Zhang","year":"2015","journal-title":"Cell Mol Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/art.39607","article-title":"Distinct Functions of Autoantibodies Against Interferon in Systemic Lupus Erythematosus: A Comprehensive Analysis of Anticytokine Autoantibodies in Common Rheumatic Diseases","volume":"68","author":"Gupta","year":"2016","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2014.00252","article-title":"Structured Evaluation of Rodent Behavioral Tests Used in Drug Discovery Research","volume":"8","author":"H\u00e5nell","year":"2014","journal-title":"Front Behav Neurosci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1084\/jem.148.5.1198","article-title":"Spontaneous Murine Lupus-Like Syndromes. Clinical and Immunopathological Manifestations in Several Strains","volume":"148","author":"Andrews","year":"1978","journal-title":"J Exp Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180392","article-title":"Primary Versus Secondary Sj\u00f6gren Syndrome: Is It Time To Reconsider These Terms","volume":"46","author":"Mavragani","year":"2019","journal-title":"J Rheumatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jaut.2012.05.008","article-title":"Sj\u00f6gren\u2019s Syndrome at the Crossroad of Polyautoimmunity","volume":"39","author":"Amador-Patarroyo","year":"2012","journal-title":"J Autoimmun"},{"key":"B48","doi-asserted-by":"publisher","first-page":"254319","DOI":"10.1155\/2012\/254319","article-title":"Introducing Polyautoimmunity: Secondary Autoimmune Diseases No Longer Exist","volume":"2012","author":"Rojas-Villarraga","year":"2012","journal-title":"Autoimmune Dis"},{"key":"B49","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13075-015-0798-8","article-title":"Low-Intensity Pulsed Ultrasound Rescues Insufficient Salivary Secretion in Autoimmune Sialadenitis","volume":"17","author":"Sato","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"B50","first-page":"9","article-title":"MRL\/lpr Mice Produce Anti-Ro 52,000 MW Antibodies: Detection, Analysis of Specificity and Site of Production","volume":"83","author":"Wahren","year":"1994","journal-title":"Immunology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3899\/jrheum.190820","article-title":"The MRL\/lpr Mouse Model: An Important Animal Model for Systemic Sj\u00f6gren Syndrome and Polyautoimmunity","volume":"47","author":"Killian","year":"2019","journal-title":"J Rheumatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"20373","DOI":"10.1038\/srep20373","article-title":"Phenotypic and Functional Alterations of pDCs in Lupus-Prone Mice","volume":"6","author":"Zhou","year":"2016","journal-title":"Sci Rep"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.2174\/1573397113666170125122858","article-title":"Unique Phenotypes and Functions of Follicular Helper T Cells and Regulatory T Cells in Sj\u00f6gren\u2019s Syndrome","volume":"14","author":"Saito","year":"2018","journal-title":"Curr Rheumatol Rev"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02661","article-title":"Ly9 (CD229) Antibody Targeting Depletes Marginal Zone and Germinal Center B Cells in Lymphoid Tissues and Reduces Salivary Gland Inflammation in a Mouse Model of Sj\u00f6gren\u2019s Syndrome","volume":"9","author":"Pu\u00f1et-Ortiz","year":"2018","journal-title":"Front Immunol"},{"key":"B55","article-title":"Fluctuation of Anti-Ro\/SS-A Antibody Levels in Patients With Systemic Lupus Erythematosus and Sj\u00f6gren\u2019s Syndrome: A Prospective Study","volume":"17","author":"Praprotnik","year":"1999","journal-title":"Clin Exp Rheumatol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.141101","article-title":"Active Immunisation of Human Interferon \u03b1 Transgenic Mice With a Human Interferon \u03b1 Kinoid Induces Antibodies That Neutralise Interferon \u03b1 in Sera From Patients With Systemic Lupus Erythematosus","volume":"70","author":"Mathian","year":"2011","journal-title":"Ann Rheumatol Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.666134\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T07:38:29Z","timestamp":1637134709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.666134\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,17]]},"references-count":56,"alternative-id":["10.3389\/fimmu.2021.666134"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.666134","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,17]]},"article-number":"666134"}}